• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TrialNetworks Vivek Murthy nominated U.S. Surgeon General

TrialNetworks Vivek Murthy nominated U.S. Surgeon General

November 19, 2013
CenterWatch Staff

TrialNetworks co-founder and chairman Vivek Murthy, M.D., MBA, has been nominated to be the 19th Surgeon General of the U.S. by President Barack Obama.

Murthy currently is an attending physician at Brigham and Women’s Hospital and an instructor at Harvard Medical School. In 2011, President Obama appointed Murthy to the Advisory Group on Prevention, Health Promotion and Integrative and Public Health. His past research has focused on the participation of women and minorities in cancer clinical trials.

Murthy co-founded TrialNetworks with CEO Eric Silberstein (his Harvard University classmate) and chief technology officer Ezra Freedman.

“Murthy’s focus has always been on using his experience in medicine and science to find ways to help patients and improve healthcare on a broad scale,” said Silberstein. “His vision and insights led to the creation of TrialNetworks and our Clinical Trial Optimization System, which enables pharmaceutical companies to bring novel therapies to patients faster by running more efficient and higher-quality trials.”

Upon confirmation by the U.S. Senate, Murthy will step down as chairman of TrialNetworks.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing